200572-36-7

Basic information

• Product Name: Pentanedioic acid, 2-cyano-3-(4-fluorophenyl)-, dimethyl ester
• CAS NO: 200572-36-7
• Molecular Formula: C14H14FNO4
• Molecular Weight: 279.268
• Mol File: 200572-36-7.mol

Chemical Properties

• CAS DataBase Reference: Pentanedioic acid, 2-cyano-3-(4-fluorophenyl)-, dimethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Pentanedioic acid, 2-cyano-3-(4-fluorophenyl)-, dimethyl ester(200572-36-7)
• EPA Substance Registry System: Pentanedioic acid, 2-cyano-3-(4-fluorophenyl)-, dimethyl ester(200572-36-7)

Safety Data

• Hazardous Substances Data: 200572-36-7(Hazardous Substances Data)

Upstream product

• 459-57-4 4-fluorobenzaldehyde 
• 105-34-0 methyl 2-cyanoacetate 
• 96426-60-7 methyl (2E)-3-(4-fluorophenyl)-2-propenoate 

Downstream Products

• 188869-26-3 (3SR,4RS)-trans-4-(4-fluorophenyl)-3-hydroxymethylpiperidine 
• 125224-43-3 (3S,4R)-trans-4-(4-fluorophenyl)-3-hydroxymethylpiperidine 
• 200572-35-6 (3S,4R)-1-(tert-butoxycarbonyl)-4-(p-fluorophenyl)-3-[3,4-(methylenedioxy)phenoxymethyl]piperidine 
• 200572-34-5 (3S,4R)-tert-butyl 4-(4-fluorophenyl)-3-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate 
• 200572-33-4 (3S,4R)-4-(4-fluorophenyl)-3-hydroxymethylpiperidine-1-carboxylic acid tert-butyl ester 
• 110429-35-1 (-)-paroxetine hydrochloride 
• 200572-39-0 (+/-)-cis,trans-4-(4-fluorophenyl)-5-methoxycarbonylpiperidin-2-one 

Relevant articles and documents

Improved synthesis of paroxetine hydrochloride propan-2-ol solvate through one of metabolites in humans, and characterization of the solvate crystals

Paroxetine, a potent and selective inhibitor of 5-hydroxytryptamine (serotonin) uptake, was prepared through a piperidine derivative, which was reported to be one of the paroxetine metabolites in humans. Thus, the piperidine derivative was converted to its N-tert-butoxycarbonyl (N-Boc) derivative, which was then converted to N-Boc paroxetine. Paroxetine hydrochloride propan-2-ol (isopropyl alcohol (IPA)) solvate crystals were directly obtained from the N-Boc paroxetine by adding hydrogen chloride to the N-Boc paroxetine IPA solution. The amount of IPA content in the crystals was reduced by drying with a continuous change of powder X-ray diffraction patterns. Other characterizations of the solvate crystals were also conducted.

Piperidine derivative and process for preparing the same

A piperidine derivative, which can be used as an intermediate for pharmaceuticals such as paroxetine useful as antidepressants, represented by the general formula (I): STR1 wherein R1 is hydrogen atom, benzyloxycarbonyl group or tert-butoxycarbonyl group; R2 is hydroxymethyl group, an alkylsulfonyloxymethyl group having an alkyl moiety of 1 to 2 carbon atoms, phenylsulfonyloxymethyl group which may have methyl group at the 4-position, (3,4-methylenedioxyphenyl)oxymethyl group, carboxyl group or --CO2 R7 group in which R7 is an alkyl group having 1 to 5 carbon atoms, and Z is methylene group or carbonyl group.